Five years after Alex Trebek shared publicly his diagnosis of stage IV metastatic pancreatic cancer, therapies for the disease remain few, and limited to specific patient subgroups. Metastatic pancreatic cancer…
More than two weeks after Pfizer (NYSE: PFE) and Novo Nordisk (NASDAQ Copenhagen: NOVO-B) slugged it out for Metsera (NASDAQ: MTSR), biopharma found itself in the grip of another bidding…
Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, then dropped on Thursday,…
Credit: TopMicrobialStock / Adobe Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin amyloidosis…
Hernan Bazan, MD, CEO and co-founder of South Rampart Pharma with Josh Blacher, MBA, chief financial officer. South Rampart Pharma is working to develop an oral small molecule non-opioid pain…
uniQure has acknowledged that what it called “game changing” data in September showing significant slowing of Huntington’s disease (HD) progression in patients treated with its gene therapy candidate AMT-130 may…
John Leonard, MD, Intellia Therapeutics president and CEO Addressing analysts in August, Intellia Therapeutics (NASDAQ: NTLA) president and CEO John Leonard, MD, announced that, given greater-than-expected patient enrollment in a…
Intent on growing its leading position in obesity and weight management drugs, Novo Nordisk has made an unsolicited, approximately up-to-$9 billion bid for Metsera—more than a month after Pfizer announced…
Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized microglial immune cells that…
Electra Therapeutics researchers at work. Electra has completed an oversubscribed $183 million Series C financing it said will fund a global pivotal trial of its lead pipeline candidate, a frontline…